Alto Neuroscience, Inc.: updates and filings

ANRONYSEHealthcare · Pharmaceutical Preparations

Price

$25.37

November 20, 2026Market cap $1.0B

What Ploutos Investor adds for Alto Neuroscience

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 16, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Oct 30, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 27, 2026Officer or director change
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 12, 2026Results of operations
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 20, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 14, 2026Material agreement entered
    Form8-K
  • Jul 13, 2026Results of operations, other material events
    Form8-K
  • May 28, 2026Officer or director change
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 15, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 13, 2026Officer or director change, shareholder vote
    Form8-K
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 13, 2026Results of operations
    Form8-K
  • Apr 20, 2026Filing
    FormEFFECT
  • Apr 17, 2026Correspondence with the SEC
    FormCORRESP
  • Apr 16, 2026Letter from the SEC
    FormUPLOAD
  • Apr 10, 2026Shelf registration for future offerings
    FormS-3

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 22, 2023.

The full analysis

What do Alto Neuroscience's filings show?

The filings are where every one of Alto Neuroscience's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.